| Name | Title | Contact Details |
|---|
At Clinipace, a global, full-service contract research organization (CRO), our approach to clinical research is personal. We deliver a level of collaboration and flexibility not possible in a traditional CRO environment. Our personalized services and solutions, local regulatory expertise and therapeutic leadership are designed to face the most difficult industry challenges across all major therapeutic areas including oncology, gastroenterology, nephrology and urology. We strive to improve the way clinical research is performed and impact the future of health care using the most advanced technology and a CHALLENGE ACCEPTED approach. In April 2021, Clinipace & dMed merged creating a differentiated mid-size CRO with the largest Asia-Pacific presence. We are proud to have such a strong group of global investors focused on improving healthcare outcomes and giving sponsors a better CRO choice. dMed`s 2019 acquisition of Target Health commenced the process of building a Next Generation global CRO for biotech and pharmaceutical companies. Our investors have invested over $230M to build the next great global CRO. dMed`s acquisition of Target Health in 2019 began dMed`s evolution from a local to global CRO. Target Health LLC is owned by dMedClinical Co. Ltd., a privately held company that is majority owned, operated, managed, and controlled by a U.S. citizen and foreign entities located in the People`s Republic of China. Dr. Lingshi Tan, is the aforementioned U.S. citizen currently residing in Shanghai, China. Dr. Tan moved to Shanghai (from New York) to become Pfizer`s VP of Worldwide Development Operations, and Chairman and General Manager of Pfizer (China) Research & Development Co. Dr. Tan founded dMed in 2016 to satisfy the local demand for a high quality, responsive, flexible CRO.
At Vireo Systems we develop, manufacture and market products and brands that enhance the health of humans and animals. Our company is dedicated to maintaining excellence in all production processes and protecting the environment while delivering safe, ...
Tucson Medical Center, licensed at 607 beds, has been Tucson`s locally governed nonprofit regional hospital for 70 years. TMC is Southern Arizona`s leading provider for emergency care and pediatric care (including Tucson`s first Pediatric Emergency Department), with top-notch intensive care units for adults, children and newborns. Other specialty areas include women`s, maternity, cardiovascular, orthopaedic, neuroscience, hospice, imaging and senior services. TMC earned certification as a Primary Stroke Center, accreditation as a Chest Pain Center, and the Gold Plus Achievement Award for stroke programs from the American Heart Association/American Stroke Association. TMC is also a recipient of the AHA/ASA`s Target: Stroke Honor Roll. TMC HealthCare is Southern Arizona`s locally governed nonprofit system, the corporate entity that includes Tucson Medical Center and Saguaro Physicians.
MBF Healthcare Partners is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PharmaBlock Sciences (Nanjing), Inc. is a leading innovative chemistry products and services provider throughout the pharmaceutical R&D process. Its core businesses include: a catalog of specially designed scaffolds and building blocks; custom synthesis; process development; manufacturing of key intermediates and RSMs; and FTE services. The company was listed on Shenzhen Exchange Stock in China on November 10, 2017. PharmaBlock has rapidly gained recognition for its outstanding capability in the design, synthesis, and supply of lab scale building blocks. Building on that success, the company acquired Shandong Diai Biotechnology Co., Ltd. as its pilot plant and manufacturing site in 2016, and is providing scale-up synthesis and manufacturing of key intermediates/RSMs. PharmaBlock is now committed to a more comprehensive and long-term service to valued customers.